Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses.

This study examines the effectiveness of a one-time shot of a recombinant canarypox virus vaccine in guarding horses against West Nile virus (WNV). The vaccine was found to provide early protection even in the absence of measurable antibodies, suggesting its potential to be a key tool in controlling WNV outbreaks in horses.

Research Design

• The researchers conducted a blind challenge trial on a sample of twenty mixed-breed horses that had never been exposed to West Nile Virus (WNV).
• The horses got randomly assigned to two groups, with one group receiving a one-time injection of a recombinant canarypox virus vaccine against WNV, and the other group serving as the control.
• The control group of horses was left untreated. On the 26th day after vaccination, both groups got exposed to WNV through mosquito bites.
• The teams noted and analyzed any clinical responses, isolated the WNV, and studied the antibody responses against WNV after vaccination and exposure.

Research Findings

• After being exposed to WNV-infected mosquitoes, only one horse from the treated group showed signs of viremia, compared with eight from the control group.
• Despite the vaccine’s apparent efficacy, it’s worth noting that all horses, including those in the control group, eventually developed immunity to WNV. However, the treated horses showed earlier detection of antibodies against the virus.
• The vaccine’s ability to provide early protection against viremia even without high antibody titers in some horses was a significant finding.

Implications of the Study

• The results suggest that the recombinant canarypox virus-WNV vaccine could be an important tool in the fight against WNV outbreaks among horses.
• The vaccine’s early protection could be particularly useful during a natural WNV outbreak or in situations where immediate protection is necessary.